Cardiol Therapeutics (CRDL) to present Phase II ARCHER trial results at ESC meeting

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. filed a Form 6-K as a foreign private issuer that reports under Form 40-F. The filing mainly furnishes a news release dated November 5, 2025, announcing that results from its Phase II ARCHER clinical trial will be presented at the European Society of Cardiology’s Scientific Meeting on Myocardial & Pericardial Diseases.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated November 5, 2025 - Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: November 5, 2025	By:	/s/ Chris Waddick
		Chris Waddick
	Title:	Chief Financial Officer

FAQ

What did Cardiol Therapeutics (CRDL) disclose in its November 2025 Form 6-K?

Cardiol Therapeutics filed a Form 6-K noting it reports under Form 40-F and furnishing a news release dated November 5, 2025. The release announces that Phase II ARCHER trial results will be presented at a major European cardiology scientific meeting.

What is the key announcement in Cardiol Therapeutics’ November 5, 2025 news release?

The key announcement is that Phase II ARCHER trial results will be presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases. This indicates Cardiol’s clinical research is being highlighted in a recognized cardiovascular scientific forum.

What type of SEC filer is Cardiol Therapeutics (CRDL) in this 6-K?

Cardiol Therapeutics is a foreign private issuer that files its annual reports under Form 40-F. The November 2025 Form 6-K serves to transmit a specific news release about its Phase II ARCHER trial presentation to U.S. investors and regulators.

When was the Cardiol Therapeutics Phase II ARCHER trial news release dated?

The news release attached to the filing is dated November 5, 2025. On that date, Cardiol Therapeutics announced that Phase II ARCHER trial results would be presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases.

Where will Cardiol Therapeutics’ Phase II ARCHER trial results be presented?

The Phase II ARCHER trial results will be presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases. This scientific event focuses on myocardial and pericardial disorders and provides a platform for sharing cardiovascular research findings.